Sugi Predict

Sugi Predict / Compounds / SCHEMBL116361

SCHEMBL116361

SCHEMBL116361

Nc1ccc(NC(=O)C2CC2)cc1

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ NAMPT P43490 2/20 0.67
▸ KMT2A Q03164 4/20 0.65
▸ MEN1 O00255 3/20 0.65
▸ LMNA P02545 2/20 0.65
▸ MAPT P10636 3/20 0.62
▸ GAA P10253 2/20 0.62
▸ GFER P55789 1/20 0.62
▸ PTPN1 P18031 1/20 0.59
▸ RAB9A P51151 6/20 0.57
▸ NPC1 O15118 3/20 0.57
▸ KDM4E B2RXH2 1/20 0.57
▸ CASP3 P42574 1/20 0.57
▸ SMN1; SMN2 Q16637 1/20 0.57
▸ SENP7 Q9BQF6 1/20 0.57
▸ HPGD P15428 1/20 0.55
▸ NPSR1 Q6W5P4 1/20 0.54
▸ GLA P06280 1/20 0.54
▸ RXFP1 Q9HBX9 1/20 0.54
▸ EPHX1 P07099 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23898941 1.00 NAMPT (0.67) NAMPTKMT2AMEN1LMNAMAPT
SCHEMBL23899043 1.00 NAMPT (0.67) NAMPTKMT2AMEN1LMNAMAPT
SCHEMBL4448787 0.92 PTPN1 (0.71) NAMPTKMT2AMEN1LMNAMAPT
SCHEMBL678484 0.91 PTPN1 (0.74) NAMPTKMT2AMEN1LMNAMAPT
SCHEMBL2717891 0.88 ULK1 (0.60) NAMPTKMT2AMEN1LMNAMAPT
SCHEMBL3093740 0.88 ALDH1A1 (0.55) NAMPTKMT2AMEN1LMNAMAPT
SCHEMBL14618675 0.82 NAMPT (0.69) NAMPTKMT2AMEN1LMNAMAPT
SCHEMBL25845705 0.81 NAMPT (0.62) NAMPTKMT2AMEN1LMNAMAPT
SCHEMBL4564743 0.80 ULK1 (0.64) NAMPTKMT2ALMNAMAPTGAA
SCHEMBL13203721 0.80 NPY5R (0.56) NAMPTKMT2AMEN1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230133132-A1 NAMPT MODULATORS CYTOKINETICS, INC. 2023-05-04 — — US disclosed
CN-107635553-B Pyrimidine derivatives as kinase inhibitors and their therapeutic use 常山凯捷健生物药物研发（河北）有限公司 2020-08-14 — — CN disclosed
EP-3261638-B1 PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS NANTBIOSCIENCE INC (US) 2019-05-08 — — EP disclosed
US-20180215734-A1 PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS NANTBIOSCIENCE, INC. 2018-08-02 — — US disclosed
CN-107635553-A Pyrimidine derivatives as kinase inhibitors and their therapeutic use 南特生物科学公司 2018-01-26 — — CN disclosed
EP-3261638-A1 PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS NantBioScience, Inc. (US) 2018-01-03 — — EP disclosed
WO-2016138527-A1 PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS NANTBIOSCIENCE, INC. (US) 2016-09-01 — — WO disclosed
EP-2424859-B1 INHIBITORS OF PI3 KINASE AND / OR MTOR AMGEN INC (US) 2015-04-08 — — EP disclosed
US-8772480-B2 Inhibitors of PI3 kinase and/or mTOR AMGEN INC. (US) 2014-07-08 — — US disclosed
US-20130079303-A1 Inhibitors of PI3 Kinase and/or mTOR AMGEN INC. (US) 2013-03-28 — — US disclosed
WO-2010126895-A1 INHIBITORS OF PI3 KINASE AND / OR MTOR AMGEN INC. (US) 2010-11-04 — — WO disclosed
US-20100273764-A1 INHIBITORS OF PI3 KINASE AND/OR MTOR AMGEN INC. (US) 2010-10-28 — — US disclosed
EP-1812424-A4 KINASE INHIBITORS MIIKANA THERAPEUTICS INC (US) 2009-07-08 — — EP disclosed
US-7449477-B2 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (protein kinase B) ELI LILLY AND COMPANY (US) 2008-11-11 — — US disclosed
US-20080200485-A1 Kinase Inhibitors MIIKANA THERAPEUTICS, INC. 2008-08-21 — — US disclosed
WO-2008079719-A1 PYRIMIDINE KINASE INHIBITORS GENENTECH, INC. (US) 2008-07-03 — — WO disclosed
CN-101084214-A Kinase inhibitors MIIKANA THERAPEUTICS INC (US) 2007-12-05 — — CN disclosed
EP-1812424-A2 KINASE INHIBITORS Miikana Therapeutics, Inc. (US) 2007-08-01 — — EP disclosed
US-20070037796-A1 e.g. 7-Phenyl-isoquinoline-5-sulfonic acid {2-[3 -(4-nitrophenyl)-propylamino]-ethyl}-amide, dihydrochloride salt; antiviral, antineoplastic, anticarcinogenic agents; neoplasms ELI LILLY AND COMPANY 2007-02-15 — — US disclosed
WO-2006055831-A2 KINASE INHIBITORS MIIKANA THERAPEUTICS, INC. (US) 2006-05-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273764-A1 INHIBITORS OF PI3 KINASE AND/OR MTOR MTOR, PIK3CA, PIK3CD NAMPT 897/4885KMT2A 3411/4885MEN1 950/4885
US-20180215734-A1 PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS DCK, TK1, DTYMK NAMPT 403/4885KMT2A 1204/4885MEN1 3796/4885
US-20080200485-A1 Kinase Inhibitors AURKC, AURKA, AURKB NAMPT 2158/4885KMT2A 887/4885MEN1 2003/4885
US-20230133132-A1 NAMPT MODULATORS NAMPT, MC4R, SIRT1 NAMPT 1/4885KMT2A 1669/4885MEN1 484/4885
US-20070037796-A1 e.g. 7-Phenyl-isoquinoline-5-sulfonic acid {2-[3 -(4-nitrophenyl)-propylamino]-ethyl}-amide, dihydrochloride salt; antiviral, antineoplastic, anticarcinogenic agents; neoplasms POLI, HRAS, CHUK NAMPT 1237/4885KMT2A 1770/4885MEN1 2522/4885
US-20130079303-A1 Inhibitors of PI3 Kinase and/or mTOR MTOR, PIK3CA, PIK3CD NAMPT 897/4885KMT2A 3411/4885MEN1 950/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.